Skip to main content

Table 1 The 50 % inhibitory concentration (IC50) of cisplatin in A549 and A549/DDP cells 48 h after drug treatment

From: RNA interferences targeting the Fanconi anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells

Cell

Control

siFANCF

siFANCL

siFANCF+

siFANCD2

siFANCD2+

siFANCD2+

siFANCL

 

siFANCF

siFANCL

A549

4.97 ± 0.32

3.05 ± 0.24a

2.46 ± 0.21b

2.44 ± 0.27 b

2.48 ± 0.31 b

2.45 ± 0.18 b

2.40 ± 0.23 b

A549/DDP

34.15 ± 0.42

4.43 ± 0.28c

2.51 ± 0.33c, d

2.48 ± 0.25 c, d

2.54 ± 0.17 c, d

2.52 ± 0.22 c, d

2.47 ± 0.19 c, d

SK-MES-1

9.92 ± 0.35

3.47 ± 0.25c

2.68 ± 0.29c

2.45 ± 0.32c

2.58 ± 0.23c

2.50 ± 0.33c

2.46 ± 0.35c

  1. acompared with control, p = 0.009; bcompared with control, p = 0.001; ccompared with control, p < 0.001; dcompared with siFANCF, p < 0.001